Fill out the form below or call us at (800) 345-4125.
If your clinic or pharmacy receives an FDA warning letter, subpoena, or regulatory inquiry involving GLP-1 medications, contact Health Law Alliance for guidance.
The explosive growth of GLP-1 medications has transformed the healthcare and weight-loss industries. Telehealth providers, medical spas, weight-loss clinics, and compounding pharmacies are launching GLP-1 programs across the country. At the same time, regulators and pharmaceutical manufacturers are aggressively scrutinizing these programs.
Federal agencies including the FDA, Department of Justice, DEA, and HHS-OIG are increasingly investigating how GLP-1 medications are compounded, prescribed, marketed, and dispensed. Clinics and pharmacies operating GLP-1 programs are now facing regulatory audits, warning letters, investigations, and lawsuits.
Health Law Alliance represents healthcare providers nationwide navigating GLP-1 regulatory compliance, government investigations, and enforcement actions.
Health Law Alliance works with Dr. Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA, a nationally recognized authority in pharmaceutical law and FDA regulation.
GLP-1 therapies have created one of the fastest-growing sectors in healthcare. Demand for medications has led to new telehealth models, compounding programs, and specialized weight-loss clinics. However, the regulatory framework surrounding GLP-1 programs is evolving quickly. Government agencies and pharmaceutical manufacturers are now challenging many aspects of how these programs operate.
Providers offering GLP-1 services must navigate issues involving:
Because GLP-1 programs often involve multiple providers and entities, regulators may investigate both clinics and pharmacies simultaneously.
Several government agencies are actively reviewing GLP-1 prescribing and compounding programs:
These investigations may begin with an audit, subpoena, or warning letter and can escalate into civil or criminal enforcement actions.
Healthcare providers operating GLP-1 programs may face legal exposure involving:
GLP-1 programs often grow rapidly, providers may unknowingly create regulatory risks that later trigger government investigations
Health Law Alliance brings together attorneys with extensive experience in healthcare regulation and enforcement.
The firm’s GLP-1 regulatory work is supported by Dr. Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA, who serves as Of Counsel to Health Law Alliance.
Dr. Rumore is widely recognized as one of the leading authorities on pharmaceutical law, compounding regulation, and FDA compliance. She is both a licensed pharmacist and attorney, as well as a registered U.S. patent attorney, giving her a rare combination of scientific, regulatory, and legal expertise.
Her work focuses on issues involving:
This combined legal and pharmaceutical expertise allows Health Law Alliance to provide highly specialized guidance for providers operating GLP-1 programs.
As Seen On
.avif)
Former Government Regulators on Your Side – Our team of healthcare defense specialists is spearheaded by former federal and state prosecutors who understand how the government and its contractors use data mining and proprietary algorithms to identify potential Fraud, Waste & Abuse (FWA) for audits and investigation. Because we understand how the government builds cases, we use their playbook to beat them.
Healthcare Specialty Attorneys and Consultants – Health Law Alliance specializes in healthcare law and is dedicated to defending providers and their licenses from overreach. Our founding partner previously served as a top executive for the biggest companies in healthcare, including McKesson, Relay Health, CoverMyMeds, United Health Group, Optum, and United Healthcare. We know the tricks insurance companies use to deny claims, and use that inside information against them.
Proven Track Record – Some clients turn to us when stakes are the highest, when their businesses are threatened, when their license is challenged, and when their options are limited. Our wins against the government and insurance companies can be reviewed HERE. Many more clients, however, turn to us at the first sign of potential trouble, when we can neutralize the problem before it grows. Either way, we have your back from beginning to end.
Can pharmacies still compound GLP-1 medications in 2026?
Compounding pharmacies may compound GLP-1 receptor agonist under certain circumstances, but the regulatory environment is changing rapidly. Federal law generally prohibits compounding drugs that are “essentially copies” of FDA-approved medications, unless certain conditions apply, such as drug shortages or patient-specific clinical differences.
Because the FDA’s guidance and supply conditions are evolving, pharmacies offering compounded GLP-1 therapies should regularly review their practices with experienced regulatory counsel.
Is compounded GLP-1 medication legal?
Compounded GLP-1 receptor agonists can be lawful when prepared by licensed compounding pharmacies operating under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. However, pharmacies must comply with strict requirements involving:
Regulators are increasingly reviewing GLP-1 compounding programs, particularly those involving telehealth or high-volume dispensing.
Why are GLP-1 clinics and telehealth providers being investigated?
The rapid expansion of GLP-1 weight-loss programs has drawn scrutiny from regulators concerned about patient safety, marketing practices, and regulatory compliance.
Investigations often focus on:
These investigations may involve the FDA, DOJ, DEA, and state licensing boards.
Who is the GLP-1 legal expert at Health Law Alliance?
Health Law Alliance’s GLP-1 regulatory practice is supported by Dr. Martha M. Rumore, one of the leading experts in pharmaceutical law and compounding regulation.
Dr. Rumore’s combined background as a pharmacist, attorney, and patent attorney allows her to address the complex scientific and regulatory issues involved in GLP-1 medications.
Her expertise helps pharmacies and clinics navigate emerging legal challenges involving GLP-1 therapies.
When should a clinic or pharmacy contact a GLP-1 attorney?
Healthcare providers should consider consulting a GLP-1 attorney if they:
Seeking legal guidance early can help providers protect their licenses, operations, and reputation.
Speak With a GLP-1 Attorney
If your clinic, pharmacy, or telehealth program receives regulatory inquiries related to GLP-1 medications, early legal guidance can make a critical difference.
Health Law Alliance represents healthcare providers nationwide navigating the complex legal landscape surrounding GLP-1 regulatory compliance.
Contact Health Law Alliance to discuss your situation and protect your practice.
Speak to an experienced attorney today at no-cost to evaluate your situation and discuss how we can help.
